{"id":773939,"date":"2023-07-31T20:27:14","date_gmt":"2023-08-01T00:27:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\/"},"modified":"2023-07-31T20:27:14","modified_gmt":"2023-08-01T00:27:14","slug":"dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\/","title":{"rendered":"DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"right\">Montrouge, France, July 31, 2023<\/p>\n<p align=\"justify\">\n        <strong>DBV Technologies <\/strong><br \/>\n        <strong>Receives Feedback from FDA on <\/strong><br \/>\n        <strong>Design <\/strong><br \/>\n        <strong>Elements <\/strong><br \/>\n        <strong>for <\/strong><br \/>\n        <strong>Viaskin Peanut <\/strong><br \/>\n        <strong>Safety Stud<\/strong><br \/>\n        <strong>ies<\/strong><br \/>\n        <strong>and <\/strong><br \/>\n        <strong>Reports <\/strong><br \/>\n        <strong>Second <\/strong><br \/>\n        <strong>Quarter<\/strong><br \/>\n        <strong>and<\/strong><br \/>\n        <strong> Half-Year <\/strong><br \/>\n        <strong>2023<\/strong><br \/>\n        <strong> Financial Results<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong>R<\/strong><br \/>\n          <strong>eceived <\/strong><br \/>\n          <strong>feedback <\/strong><br \/>\n          <strong>from U.S. Food and Drug Administration (FDA) <\/strong><br \/>\n          <strong>on <\/strong><br \/>\n          <strong>DBV\u2019s<\/strong><br \/>\n          <strong> two supplemental safety stud<\/strong><br \/>\n          <strong>ies<\/strong><br \/>\n          <strong> in toddlers <\/strong><br \/>\n          <strong>(<\/strong><br \/>\n          <strong>ages <\/strong><br \/>\n          <strong>1<\/strong><br \/>\n          <strong> \u2013 <\/strong><br \/>\n          <strong>3 years) <\/strong><br \/>\n          <strong>and children<\/strong><br \/>\n          <strong> (<\/strong><br \/>\n          <strong>ages <\/strong><br \/>\n          <strong>4<\/strong><br \/>\n          <strong> \u2013 7<\/strong><br \/>\n          <strong> years)<\/strong><br \/>\n          <strong>.<\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong>The two <\/strong><br \/>\n          <strong>Phase 3 pivotal <\/strong><br \/>\n          <strong>safety <\/strong><br \/>\n          <strong>studies will be named COMFORT Toddlers<\/strong><br \/>\n          <strong> (1 \u2013 3 years) and COMFORT Children (4 \u2013 7 years).<\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong>COMFORT Toddlers<\/strong><br \/>\n          <strong> will be a 6-month <\/strong><br \/>\n          <strong>safety <\/strong><br \/>\n          <strong>study, <\/strong><br \/>\n          <strong>consistent with agreement previously reached with FDA on the <\/strong><br \/>\n          <strong>COMFORT Children safety study.<\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong>The Company <\/strong><br \/>\n          <strong>expects to <\/strong><br \/>\n          <strong>seek <\/strong><br \/>\n          <strong>final<\/strong><br \/>\n          <strong> alignment<\/strong><br \/>\n          <strong>with<\/strong><br \/>\n          <strong> FDA<\/strong><br \/>\n          <strong>on the COMFORT protocols <\/strong><br \/>\n          <strong>prior to commencing the studies<\/strong><br \/>\n          <strong>.<\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong>DBV closes Q2 2023 with a cash balance of $174<\/strong><br \/>\n          <strong> million<\/strong><br \/>\n          <strong>.<\/strong><\/p>\n<\/li>\n<\/ul>\n<p align=\"justify\">DBV Technologies (Euronext: DBV \u2013 ISIN: FR0010417345 \u2013 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the receipt of Written Responses from the FDA on key study design elements for the COMFORT (<strong>C<\/strong>haracterization of the <strong>O<\/strong>ptimal <strong>M<\/strong>anagement of <strong>FO<\/strong>od Allergy <strong>R<\/strong>elief and <strong>T<\/strong>reatment) Toddlers and COMFORT Children  supplemental safety studies in 1 \u2013 3-year-olds and 4 \u2013 7-year-olds, respectively, with a peanut allergy. The Company also reported financial results for the second quarter and the first half of 2023. The quarterly and half-year financial statements were approved by the Board of Directors on July 28, 2023.<\/p>\n<p align=\"justify\">\n        <strong>Recent <\/strong><br \/>\n        <strong>B<\/strong><br \/>\n        <strong>usiness <\/strong><br \/>\n        <strong>Developments<\/strong>\n      <\/p>\n<p align=\"justify\">Viaskin\u2122 Peanut in 1 \u2013 3-year-olds (original square patch) and Viaskin\u2122 Peanut in 4 \u2013 7-year-olds (modified circular patch) are separate product candidates with independent clinical and regulatory paths supporting two distinct Biologics License Applications (BLAs). <\/p>\n<p align=\"justify\">DBV received Type C Meeting Written Responses from the FDA on the two supplemental safety studies, known as COMFORT. The COMFORT Toddlers safety study will enroll peanut allergic toddlers ages 1 \u2013 3-years and will support the efficacy results generated from the EPITOPE Phase 3 pivotal study. The COMFORT Children safety study will enroll peanut allergic children ages 4 \u2013 7-years and will support the efficacy results anticipated from the ongoing VITESSE Phase 3 pivotal study.<\/p>\n<p align=\"justify\">The FDA agreed with a 6-month study duration and a 3:1 randomization (active:placebo) of approximately 400 subjects in the double-blind, placebo-controlled COMFORT Toddlers study. Both COMFORT studies will assess adhesion using the same tools and measurements that were established in VITESSE. Neither the COMFORT Toddlers study nor the COMFORT Children study will require an oral food challenge for participation.<\/p>\n<p align=\"justify\">The feedback received is consistent with FDA\u2019s position on COMFORT Children in\u00a0\u00a0 4 \u2013 7-year-olds, as previously announced in <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Vav8krZQfVWyNCov8fhAX0vEzLYFsfbOfAtDBXeIskNoaW7EkFovMFRrxyc0Q52v_LNxftVNQPfMdX5Snk96gEnTKaIRIxfAnzHQQzfpwImVgusFQV0scwFKgVALPp73w656jcOEiCscAOs86RgcDLHAzdTnvhZaJxQBOOajpLfZQ_mkH5LXMwHnGCYAuo-6\" rel=\"nofollow noopener\" target=\"_blank\">December 2022<\/a>.<\/p>\n<p align=\"justify\">Both COMFORT studies aim to bring the total number of subjects on active treatment to approximately 600 participants in each age group, when added to their respective Phase 3 pivotal efficacy studies (i.e., EPITOPE and VITESSE). <\/p>\n<p align=\"justify\">\u201c<em>We are pleased to<\/em><em> have <\/em><em>received <\/em><em>feedback <\/em><em>from the FDA on <\/em><em>key design elements for the COMFORT safety study protocols in 1 \u2013 3 and 4 \u2013 7-year-olds with peanut allergy<\/em>,\u201d said <strong>Daniel Tass<\/strong><strong>\u00e9<\/strong><strong>, Chief Executive Officer, DBV Technologies<\/strong>. \u201c<em>This continues the <\/em><em>positive <\/em><em>momentum DBV received in <\/em><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Vav8krZQfVWyNCov8fhAXwhDguFvSr-H3mJDKg8YJQaRZHbRHczNl5OVSB5fSQUkV3GJfmSLHElW6AtRqyLLkqnnRXp2mbWLmRKDD1JEW4Ef0xm4w6VOMfrdisb_JtH3vk2IWB1xG4gzkRB6KrEqc1BYPbbMI9a2-VJJxJx2Ms7QS1RFqq7TJArnd8REXCHu9qveHK4m2PR1dXpwgi2y1Q==\" rel=\"nofollow noopener\" target=\"_blank\"><em>December 2022<\/em><\/a><em>and <\/em><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ktiK6hOff9hjLWkgysrfQfzCDPxd991HHuWj-opJS_hGj559BFQ65w1xd0vShGreRqTknsVP6FPVfDEaeWBENVNH5xGs9bd57fWDsQtnCS7tJUJr20PoJA1HH-D17SC6INcs0lm6VSGv5PEKwAC0_U_gntKyEdtXT6Re85IpsrwSjxJvahItt3XVHgfIdqhjHOSY9EO-4zIZR-qZRbMIxzLE62kl4RRw0mKZpfIyVAQNNyxTDH5LDSPOamuWvdwxxKROINOOUQsf0ZQ8hyDZ4A==\" rel=\"nofollow noopener\" target=\"_blank\"><em>April 2023<\/em><\/a><em> when we outlined our regulatory pathways for Viaskin Peanut in children and toddlers<\/em><em>. We <\/em><em>are<\/em><em> actively enrolling subjects in the <\/em><em>VITESSE Phase 3 study and were <\/em><em>also <\/em><em>honored to have our EPITOPE data <\/em><em>published<\/em><em> in the New England Journal <\/em><em>of Medicine in <\/em><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HpFWc3zpYRx8xNZRcsRdc6pSpG7rJ_t9tzBZY2KD_2JHtIsvTimOsIoVjTXbKiCvbE55VysAnEU-Nuh4KlG2yvYP71g171vAbTWczyXv7VMbrsvYRBTz78EOcdFX7NhTvCEjlWR8EYWCcRlpPNTq57VyoG_ksa4IflcAK7PCGyM9qb6LvqcdabjC3pHo5LPmEWQl4c8vnmLXVzeC7ImcQDF6CnRu_sIAREz4m4r6krpDDMmChX3UN_VWTWeS0rlFiAvWw6OjKjZbyXDJsvqkBz6l7PYJA-HwrkWuYfGBmXI=\" rel=\"nofollow noopener\" target=\"_blank\"><em>May<\/em><\/a><em>, with an accompanying editorial<\/em><em>.<\/em><em> The<\/em><em> COMFORT Toddlers and COMFORT Children safety studies meet the FDA\u2019s request for additional safety <\/em><em>studies<\/em><em>in these patient populations.<\/em><em>As we <\/em><em>complet<\/em><em>e<\/em><em>the<\/em><em> final<\/em><em> protocol<\/em><em>s<\/em><em>,<\/em>\u00a0\u00a0 <em>which we expect to<\/em><em> share<\/em><em> with<\/em><em> FDA<\/em><em>, we<\/em><em> are<\/em><em>actively progress<\/em><em>ing<\/em><em>site selection and <\/em><em>contracting <\/em><em>to <\/em><em>enable<\/em><em>t<\/em><em>he<\/em><em>start<\/em><em>of <\/em><em>th<\/em><em>e COMFORT<\/em><em> safety<\/em><em> studies as soon as<\/em><em> final<\/em><em> FDA <\/em><em>protocol a<\/em><em>lignment is achieved.<\/em>\u201d<\/p>\n<p align=\"justify\">\n        <strong>Conference Call<\/strong>\n      <\/p>\n<p align=\"justify\">DBV will host a conference call and live audio webcast on Monday, July 31<sup>st<\/sup>, at 5:00 p.m. ET to report first half 2023 financial results and provide a corporate update.<\/p>\n<p align=\"justify\">Participants may access this event via the below teleconferencing numbers and asking to join the DBV Technologies call: <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:left\">United States: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a01-844-481-2866 <\/li>\n<li style=\"text-align:left\">International: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0+1-412-317-1859\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/li>\n<\/ul>\n<p align=\"justify\">A live webcast of the call will be available on the Investors &amp; Media section of the Company\u2019s website: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wR2WJCeduHjQzQxqkd40RUPi07gUodv-VQZjGbXk5fgVyBYyeJSa9885DsWg58EeYK-oyvEJQvACNH9zves5MQDagxLO433XGilu-1F5eAIOiD_LMUXL_bF-gBRz61XsFMRnnLukKnNDsIoqjcWlKKgQVHOFPXomsMpAwbnJ6v7xtTw1d1rATqSo4Ihvbr78\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.dbv-technologies.com\/investor-relations\/<\/a>. A replay of the presentation will also be available on DBV\u2019s website after the event.<\/p>\n<p align=\"justify\">\n        <strong>Financial Highlights for the<\/strong><br \/>\n        <strong>Second<\/strong><br \/>\n        <strong> Quarter and the <\/strong><br \/>\n        <strong>Six<\/strong><br \/>\n        <strong> Months Ended <\/strong><br \/>\n        <strong>June<\/strong><br \/>\n        <strong> 3<\/strong><br \/>\n        <strong>0<\/strong><br \/>\n        <strong>, 2023<\/strong>\n      <\/p>\n<p align=\"justify\">The Company\u2019s interim consolidated financial statements for the six months ended June 30, 2023, are prepared in accordance with both generally accepted accounting principles in the U.S. (\u201cU.S. GAAP\u201d) and International Financial Reporting Standards (\u201cIFRS\u201d) as adopted by the European Union. Unless otherwise indicated, the financial figures presented in the Q2 Financial Highlights comply with both U.S. GAAP and IFRS consolidated financial statements. The financial figures are commented for the six months ended June 30, 2023, under U.S. GAAP. Differences between U.S. GAAP and IFRS consolidated financial statements are mainly due to discrepancies arising from the application of lease accounting standards.<\/p>\n<p align=\"justify\">\n        <strong>Cash and <\/strong><br \/>\n        <strong>C<\/strong><br \/>\n        <strong>ash Equivalents<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:453.35pt;border-collapse:collapse\">\n<tr>\n<td rowspan=\"3\" style=\"width:235.94px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: justify;vertical-align: middle\">(in millions of USD)<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/td>\n<td colspan=\"2\" style=\"width:184.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>U.S. GAAP<\/strong>\n          <\/td>\n<td colspan=\"2\" style=\"width:184.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>IFRS<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" style=\"width:184.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Six months ended June 30,<\/strong>\n          <\/td>\n<td colspan=\"2\" style=\"width:184.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Six months ended June 30,<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:92.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>2023<\/strong>\n          <\/td>\n<td style=\"width:92.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>202<\/strong><br \/>\n            <strong>2<\/strong>\n          <\/td>\n<td style=\"width:92.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>2023<\/strong>\n          <\/td>\n<td style=\"width:92.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>2022<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:235.94px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Net cash &amp; cash equivalents at the beginning of the period<\/strong>\n          <\/td>\n<td style=\"width:92.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>209.2<\/strong>\n          <\/td>\n<td style=\"width:92.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>77.3<\/strong>\n          <\/td>\n<td style=\"width:92.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>20<\/strong><br \/>\n            <strong>9<\/strong><br \/>\n            <strong>.2<\/strong>\n          <\/td>\n<td style=\"width:92.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>77.3<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:235.94px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Net cash flow used in operating activities<\/td>\n<td style=\"width:92.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(46.4)<\/td>\n<td style=\"width:92.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(11.7)<\/td>\n<td style=\"width:92.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(45.4)<\/td>\n<td style=\"width:92.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(8.6)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:235.94px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Net cash flow provided by \/ (used in) investing activities<\/td>\n<td style=\"width:92.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(0.3)<\/td>\n<td style=\"width:92.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(0.2)<\/td>\n<td style=\"width:92.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(0.3)<\/td>\n<td style=\"width:92.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(0.2)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:235.94px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Net cash flow provided by \/ ((used in) financing activities<\/td>\n<td style=\"width:92.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">7.8<\/td>\n<td style=\"width:92.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">195.2<\/td>\n<td style=\"width:92.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">6.8<\/td>\n<td style=\"width:92.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">192.1<\/td>\n<\/tr>\n<tr>\n<td style=\"width:235.94px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Effect of exchange rate changes on cash &amp; cash equivalents<\/td>\n<td style=\"width:92.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">3.7<\/td>\n<td style=\"width:92.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(12.6)<\/td>\n<td style=\"width:92.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">3.7<\/td>\n<td style=\"width:92.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(12.6)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:235.94px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Net cash &amp; cash equivalents at the end of the period<\/strong>\n          <\/td>\n<td style=\"width:92.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>174.0<\/strong>\n          <\/td>\n<td style=\"width:92.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>248.0<\/strong>\n          <\/td>\n<td style=\"width:92.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>174.0<\/strong>\n          <\/td>\n<td style=\"width:92.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>248.0<\/strong>\n          <\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">Cash and cash equivalents amount to $174.0 million as of June 30, 2023, compared to $209.2 million as of December 31, 2022, which is a net decrease by $35.2 million mainly due to the following:<\/p>\n<p align=\"justify\">(1)\u00a0\u00a0\u00a0$46.4 million of cash used for operations, mainly driven by the initiation of the VITESSE trial with the first patient screened in March 2023.<\/p>\n<p>Cash used for operations in the six months ended June 30, 2023, increased by $34.7 million compared to the six months ended June 30, 2022. The Company received 24.8 million euros during the six months ended June 30, 2022, for reimbursement of 2019, 2020, and 2021 French research tax credits.<\/p>\n<p align=\"justify\">(2)\u00a0\u00a0\u00a0$7.8 million proceeds from the issuance and sale of new ordinary shares in form of American Depositary Shares (\u201cADSs\u201d) on June 16, 2023, and pursuant to the At-The-Market (\u201cATM\u201d) program established in May 2022.<\/p>\n<p>Cash provided by financing activities decreased by $187.4 million in the six months ended June 30, 2023, compared to the six months ended June 30, 2022. The Company issued and sold new ordinary shares in form of ADSs for a total gross amount of $15.3 million in May 2022, and completed a private placement financing (\u201cPIPE\u201d) amounting to $194.0 million gross in June 2022.<\/p>\n<p align=\"justify\">(3)\u00a0\u00a0\u00a0$3.7 million positive impact of changes in exchange rates. The Company\u2019s treasury position, stated in U.S. Dollars, has been impacted by an appreciation of Euro against U.S. Dollar during the six months ended June 30, 2023.<\/p>\n<p><strong>Operating <\/strong><strong>I<\/strong><strong>ncome<\/strong><\/p>\n<table style=\"border-collapse: collapse;width:460.45pt;border-collapse:collapse\">\n<tr>\n<td rowspan=\"3\" style=\"width:132px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: justify;vertical-align: middle\">In millions of USD<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/td>\n<td colspan=\"2\" style=\"width:160.6px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>U.S. GAAP<\/strong>\n          <\/td>\n<td colspan=\"2\" style=\"width:160.67px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>U.S. GAAP<\/strong>\n          <\/td>\n<td colspan=\"2\" style=\"width:160.67px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>IFRS<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" style=\"width:160.6px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Three months ended June 30,<\/strong>\n          <\/td>\n<td colspan=\"2\" style=\"width:160.67px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Six months ended June 30,<\/strong>\n          <\/td>\n<td colspan=\"2\" style=\"width:160.67px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Six months ended June 30,<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:80.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>2023<\/strong>\n          <\/td>\n<td style=\"width:80.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>2022<\/strong>\n          <\/td>\n<td style=\"width:80.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>2023<\/strong>\n          <\/td>\n<td style=\"width:80.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>2022<\/strong>\n          <\/td>\n<td style=\"width:80.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>2023<\/strong>\n          <\/td>\n<td style=\"width:80.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>2022<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:132px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Research tax credits<\/td>\n<td style=\"width:80.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">2.0<\/td>\n<td style=\"width:80.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">1.5<\/td>\n<td style=\"width:80.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">3.7<\/td>\n<td style=\"width:80.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">3.1<\/td>\n<td style=\"width:80.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">3.7<\/td>\n<td style=\"width:80.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">3.1<\/td>\n<\/tr>\n<tr>\n<td style=\"width:132px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Other operating income<\/td>\n<td style=\"width:80.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">0.3<\/td>\n<td style=\"width:80.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">&#8211;<\/td>\n<td style=\"width:80.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">0.7<\/td>\n<td style=\"width:80.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">1.0<\/td>\n<td style=\"width:80.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">0.7<\/td>\n<td style=\"width:80.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">1.0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:132px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Operating income<\/strong>\n          <\/td>\n<td style=\"width:80.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>2.3<\/strong>\n          <\/td>\n<td style=\"width:80.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>1.5<\/strong>\n          <\/td>\n<td style=\"width:80.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>4.4<\/strong>\n          <\/td>\n<td style=\"width:80.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>4.1<\/strong>\n          <\/td>\n<td style=\"width:80.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>4.4<\/strong>\n          <\/td>\n<td style=\"width:80.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>4.1<\/strong>\n          <\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">Operating income amounts to $4.4 million for the six months ended June 30, 2023, compared to $4.1 million for the six months ended June 30, 2022, which is an increase by $0.3 million due to:<\/p>\n<p align=\"justify\">(1)\u00a0\u00a0\u00a0$0.6 million increase in research tax credit estimate as costs eligible to the French tax credit increased to support research and development activities (a) after the initiation of VITESSE with the first patient screened in March 2023, and (b) as part of the new safety study for toddlers after the FDA confirmed in April 2023 additional safety data is required for BLA submission.<\/p>\n<p>(2)\u00a0\u00a0\u00a0Partially offset by a decrease by $0.3 million in other operating income that consists of revenues recognized in advance as part of the collaboration agreement with Nestl\u00e9 Health Science (\u201cNHS\u201d).<\/p>\n<p><strong>Operating Expenses<\/strong><strong>\u00a0<\/strong><\/p>\n<table style=\"border-collapse: collapse;width:460.45pt;border-collapse:collapse\">\n<tr>\n<td rowspan=\"3\" style=\"width:150.87px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: justify;vertical-align: middle\">In millions of USD<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/td>\n<td colspan=\"2\" style=\"width:154.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>U.S. GAAP<\/strong>\n          <\/td>\n<td colspan=\"2\" style=\"width:154.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>U.S. GAAP<\/strong>\n          <\/td>\n<td colspan=\"2\" style=\"width:154.4px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>IFRS<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" style=\"width:154.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Three months ended June 30,<\/strong>\n          <\/td>\n<td colspan=\"2\" style=\"width:154.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Six months ended June 30,<\/strong>\n          <\/td>\n<td colspan=\"2\" style=\"width:154.4px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Six months ended June 30,<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:77.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>2023<\/strong>\n          <\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>2022<\/strong>\n          <\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>2023<\/strong>\n          <\/td>\n<td style=\"width:77.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>202<\/strong><br \/>\n            <strong>2<\/strong>\n          <\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>202<\/strong><br \/>\n            <strong>3<\/strong>\n          <\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>202<\/strong><br \/>\n            <strong>2<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:150.87px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Research &amp; Development<\/td>\n<td style=\"width:77.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">17.6<\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">18.6<\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">33.6<\/td>\n<td style=\"width:77.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">30.8<\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">33.5<\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">30.7<\/td>\n<\/tr>\n<tr>\n<td style=\"width:150.87px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Sales &amp; Marketing<\/td>\n<td style=\"width:77.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">0.5<\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">1.0<\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">1.0<\/td>\n<td style=\"width:77.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">1.5<\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">1.0<\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">1.5<\/td>\n<\/tr>\n<tr>\n<td style=\"width:150.87px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">General &amp; Administrative<\/td>\n<td style=\"width:77.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">9.2<\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">5.7<\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">16.1<\/td>\n<td style=\"width:77.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">12.3<\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">16.2<\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">12.2<\/td>\n<\/tr>\n<tr>\n<td style=\"width:150.87px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Operating expenses<\/strong>\n          <\/td>\n<td style=\"width:77.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>27.<\/strong><br \/>\n            <strong>3<\/strong>\n          <\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>25.<\/strong><br \/>\n            <strong>3<\/strong>\n          <\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>50.7<\/strong>\n          <\/td>\n<td style=\"width:77.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>44.6<\/strong>\n          <\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>50.7<\/strong>\n          <\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>44.4<\/strong>\n          <\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">Operating expenses amount to $50.7 million for the six months ended June 30, 2023, compared to $44.6 million for the six months ended June 30, 2022, which is an increase by $6.1 million mainly due to:<\/p>\n<p align=\"justify\">(1)\u00a0\u00a0\u00a0The increase by $2.8 million in research and development expenses mainly explained by the difference in phasing of on-going clinical trials between the two compared periods, including initiation costs of the VITESSE trial with the first patient screened in March 2023.<\/p>\n<p>(2)\u00a0\u00a0\u00a0The increase by $3.8 million in general and administrative expenses mainly related to one-time costs associated with financing activities, organizational planning, market research and planning activities.<\/p>\n<p>(3)\u00a0\u00a0\u00a0Partially offset by the decrease by $0.5 million in sales and marketing expenses due to a decrease of external professional services and employee-related costs.<\/p>\n<p><strong>Net Loss and Net Loss <\/strong><strong>P<\/strong><strong>er Share<\/strong><\/p>\n<table style=\"border-collapse: collapse;width:453.6pt;border-collapse:collapse\">\n<tr>\n<td rowspan=\"3\" style=\"width:141.8px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/td>\n<td colspan=\"2\" style=\"width:154.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>U.S. GAAP<\/strong>\n          <\/td>\n<td colspan=\"2\" style=\"width:154.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>U.S. GAAP<\/strong>\n          <\/td>\n<td colspan=\"2\" style=\"width:154.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>IFRS<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" style=\"width:154.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Three months ended June 30,<\/strong>\n          <\/td>\n<td colspan=\"2\" style=\"width:154.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Six months ended June 30,<\/strong>\n          <\/td>\n<td colspan=\"2\" style=\"width:154.34px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Six months ended June 30,<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:77.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>2023<\/strong>\n          <\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>2022<\/strong>\n          <\/td>\n<td style=\"width:77.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>2023<\/strong>\n          <\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>202<\/strong><br \/>\n            <strong>2<\/strong>\n          <\/td>\n<td style=\"width:77.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>202<\/strong><br \/>\n            <strong>3<\/strong>\n          <\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>202<\/strong><br \/>\n            <strong>2<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:141.8px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Net income \/ (loss) (in millions of USD)<\/td>\n<td style=\"width:77.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(24.2)<\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(23.0)<\/td>\n<td style=\"width:77.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(44,8)<\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(39.7)<\/td>\n<td style=\"width:77.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(44.9)<\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(39.5)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:141.8px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Basic \/ diluted net income \/ (loss) per share (USD\/share)<\/td>\n<td style=\"width:77.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(0.26)<\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(0.35)<\/td>\n<td style=\"width:77.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(0.48)<\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(0.66)<\/td>\n<td style=\"width:77.14px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(0.48)<\/td>\n<td style=\"width:77.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(0.65)<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">Net result for the six months ended June 30, 2023, is a loss amounting to $44.8 million, compared to a loss amounting to $39.7 million for the six months ended June 30, 2022.<\/p>\n<p align=\"justify\">On a per share basis, net loss (based on the weighted average number of shares outstanding over the period) is $0.48 for the six months ended June 30, 2023.<\/p>\n<p align=\"left\">\n        <br \/>\n        <strong>CONDENSED CONSOLIDATED <\/strong><br \/>\n        <strong>STATEMENTS OF <\/strong><br \/>\n        <strong>FINANCIAL POSITION<\/strong><br \/>\n        <strong> (unaudited)<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:463.25pt;border-collapse:collapse\">\n<tr>\n<td rowspan=\"2\" style=\"width:188.67px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: center;vertical-align: middle\">In millions of USD<\/p>\n<p>\u00a0<\/td>\n<td colspan=\"2\" style=\"width:214.47px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>U.S. GAAP<\/strong>\n          <\/td>\n<td colspan=\"2\" style=\"width:214.54px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>IFRS<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:107.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>June 30, 2023<\/strong>\n          <\/td>\n<td style=\"width:107.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>December 31, 2022<\/strong>\n          <\/td>\n<td style=\"width:107.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>June 30, 2023<\/strong>\n          <\/td>\n<td style=\"width:107.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>December 31, 2022<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:188.67px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Assets<\/strong>\n          <\/td>\n<td style=\"width:107.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>217.5<\/strong>\n          <\/td>\n<td style=\"width:107.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>246.5<\/strong>\n          <\/td>\n<td style=\"width:107.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>217.5<\/strong>\n          <\/td>\n<td style=\"width:107.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>246.5<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:188.67px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">of which cash &amp; cash equivalents<\/td>\n<td style=\"width:107.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">174.0<\/td>\n<td style=\"width:107.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">209.2<\/td>\n<td style=\"width:107.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">174.0<\/td>\n<td style=\"width:107.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">209.2<\/td>\n<\/tr>\n<tr>\n<td style=\"width:188.67px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Liabilities<\/strong>\n          <\/td>\n<td style=\"width:107.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>53.3<\/strong>\n          <\/td>\n<td style=\"width:107.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>52.0<\/strong>\n          <\/td>\n<td style=\"width:107.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>53.2<\/strong>\n          <\/td>\n<td style=\"width:107.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>52.0<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:188.67px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Shareholders\u2019 equity<\/strong>\n          <\/td>\n<td style=\"width:107.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>164.2<\/strong>\n          <\/td>\n<td style=\"width:107.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>194.5<\/strong>\n          <\/td>\n<td style=\"width:107.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>164.3<\/strong>\n          <\/td>\n<td style=\"width:107.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>194.5<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:188.67px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">of which net result<\/td>\n<td style=\"width:107.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(44.8)<\/td>\n<td style=\"width:107.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(96.2)<\/td>\n<td style=\"width:107.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(44.9)<\/td>\n<td style=\"width:107.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(96.0)<\/td>\n<\/tr>\n<\/table>\n<p align=\"left\">\n        <strong>CONDENSED CONSOLIDATED <\/strong><br \/>\n        <strong>STATEMENTS OF <\/strong><br \/>\n        <strong>OPERATIONS <\/strong><br \/>\n        <strong>(unaudited)<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:481.7pt;border-collapse:collapse\">\n<tr>\n<td rowspan=\"3\" style=\"width:169.8px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: justify;vertical-align: middle\">In millions of USD<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/td>\n<td colspan=\"2\" style=\"width:157.47px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>U.S. GAAP<\/strong>\n          <\/td>\n<td colspan=\"2\" style=\"width:157.47px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>U.S. GAAP<\/strong>\n          <\/td>\n<td colspan=\"2\" style=\"width:157.54px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>IFRS<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" style=\"width:157.47px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Three months ended June 30,<\/strong>\n          <\/td>\n<td colspan=\"2\" style=\"width:157.47px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Six months ended June 30,<\/strong>\n          <\/td>\n<td colspan=\"2\" style=\"width:157.54px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Six months ended June 30,<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>2023<\/strong>\n          <\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>2022<\/strong>\n          <\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>2023<\/strong>\n          <\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>202<\/strong><br \/>\n            <strong>2<\/strong>\n          <\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>202<\/strong><br \/>\n            <strong>3<\/strong>\n          <\/td>\n<td style=\"width:78.8px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>202<\/strong><br \/>\n            <strong>2<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:169.8px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Revenues<\/strong>\n          <\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>2.3<\/strong>\n          <\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>1.5<\/strong>\n          <\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>4.5<\/strong>\n          <\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>4.1<\/strong>\n          <\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>4.5<\/strong>\n          <\/td>\n<td style=\"width:78.8px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>4.1<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:169.8px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Research &amp; Development<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(17.6)<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(18.6)<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(33.6)<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(30.8)<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(33.5)<\/td>\n<td style=\"width:78.8px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(30.7)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:169.8px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Sales &amp; Marketing<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(0.5)<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(1.0)<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(1.0)<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(1.5)<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(1.0)<\/td>\n<td style=\"width:78.8px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(1.5)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:169.8px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">General &amp; Administrative<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(9.2)<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(5.7)<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(16.1)<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(12.3)<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(16.2)<\/td>\n<td style=\"width:78.8px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(12.2)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:169.8px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Operating expenses<\/strong>\n          <\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>(27.<\/strong><br \/>\n            <strong>3<\/strong><br \/>\n            <strong>)<\/strong>\n          <\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>(25.3)<\/strong>\n          <\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>(50.7)<\/strong>\n          <\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>(44.<\/strong><br \/>\n            <strong>6<\/strong><br \/>\n            <strong>)<\/strong>\n          <\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>(50.7)<\/strong>\n          <\/td>\n<td style=\"width:78.8px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>(44.3)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:169.8px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Financial income\/(expenses)<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">0.8<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">0.8<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">1.4<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">0.9<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">1.4<\/td>\n<td style=\"width:78.8px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">0.8<\/td>\n<\/tr>\n<tr>\n<td style=\"width:169.8px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Income tax<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">&#8211;<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">&#8211;<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">&#8211;<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">&#8211;<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">&#8211;<\/td>\n<td style=\"width:78.8px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">&#8211;<\/td>\n<\/tr>\n<tr>\n<td style=\"width:169.8px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Net loss<\/strong>\n          <\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>(24.2)<\/strong>\n          <\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>(23.0)<\/strong>\n          <\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>(44.8)<\/strong>\n          <\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>(39.<\/strong><br \/>\n            <strong>6<\/strong><br \/>\n            <strong>)<\/strong>\n          <\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>(44.9)<\/strong>\n          <\/td>\n<td style=\"width:78.8px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>(39.5)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:169.8px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Basic\/diluted net loss per share attributable to shareholders<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(0.26)<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(0.35)<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(0.48)<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(0.66)<\/td>\n<td style=\"width:78.74px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(0.48)<\/td>\n<td style=\"width:78.8px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(0.65)<\/td>\n<\/tr>\n<\/table>\n<p align=\"left\">\n        <strong>C<\/strong><br \/>\n        <strong>ONDENSED CONSOLIDATED <\/strong><br \/>\n        <strong>STATEMENTS OF <\/strong><br \/>\n        <strong>CASH FLOW<\/strong><br \/>\n        <strong> (unaudited)<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:467.55pt;border-collapse:collapse\">\n<tr>\n<td rowspan=\"3\" style=\"width:226.47px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: justify;vertical-align: middle\">In millions of USD<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/td>\n<td colspan=\"2\" style=\"width:198.47px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>U.S. GAAP<\/strong>\n          <\/td>\n<td colspan=\"2\" style=\"width:198.47px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>IFRS<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" style=\"width:198.47px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Six months ended June 30,<\/strong>\n          <\/td>\n<td colspan=\"2\" style=\"width:198.47px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Six months ended June 30,<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:99.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>2023<\/strong>\n          <\/td>\n<td style=\"width:99.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>2022<\/strong>\n          <\/td>\n<td style=\"width:99.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>2023<\/strong>\n          <\/td>\n<td style=\"width:99.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>2022<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:226.47px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Net cash flows provided \/ (used) in operating activities<\/td>\n<td style=\"width:99.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(46.4)<\/td>\n<td style=\"width:99.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(11.7)<\/td>\n<td style=\"width:99.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(45.4)<\/td>\n<td style=\"width:99.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(8.6)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226.47px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Net cash flows provided \/ (used) in investing activities<\/td>\n<td style=\"width:99.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(0.3)<\/td>\n<td style=\"width:99.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(0.2)<\/td>\n<td style=\"width:99.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(0.3)<\/td>\n<td style=\"width:99.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(0.2)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226.47px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Net cash flows provided \/ (used) in financing activities<\/td>\n<td style=\"width:99.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">7.8<\/td>\n<td style=\"width:99.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">195.2<\/td>\n<td style=\"width:99.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">6.8<\/td>\n<td style=\"width:99.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">192.1<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226.47px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Effect of exchange rate changes on cash &amp; cash equivalents (U.S. GAAP presentation)<\/td>\n<td style=\"width:99.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">3.7<\/td>\n<td style=\"width:99.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(12.6)<\/td>\n<td style=\"width:99.2px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:99.27px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226.47px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Net increase \/ (decrease) in cash &amp; cash equivalents<\/strong>\n          <\/td>\n<td style=\"width:99.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>(35.2)<\/strong>\n          <\/td>\n<td style=\"width:99.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>170.7<\/strong>\n          <\/td>\n<td style=\"width:99.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>(38.9)<\/strong>\n          <\/td>\n<td style=\"width:99.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>183.3<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:226.47px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Net cash &amp; cash equivalents at the beginning of the period<\/td>\n<td style=\"width:99.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">209.2<\/td>\n<td style=\"width:99.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">77.3<\/td>\n<td style=\"width:99.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">209.2<\/td>\n<td style=\"width:99.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">77.3<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226.47px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Effect of exchange rate changes on cash &amp; cash equivalents (IFRS presentation)<\/td>\n<td style=\"width:99.2px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:99.27px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:99.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">3.7<\/td>\n<td style=\"width:99.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">(12.6)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:226.47px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Net cash &amp; cash equivalents at the end of the period<\/strong>\n          <\/td>\n<td style=\"width:99.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>174.0<\/strong>\n          <\/td>\n<td style=\"width:99.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>248.0<\/strong>\n          <\/td>\n<td style=\"width:99.2px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>174.0<\/strong>\n          <\/td>\n<td style=\"width:99.27px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>248.0<\/strong>\n          <\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <strong>About DBV Technologies<\/strong><br \/>\n        <br \/>DBV Technologies is developing Viaskin\u2122, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT\u2122, and is DBV Technologies\u2019 method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies\u2019 food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company\u2019s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company\u2019s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).<\/p>\n<p align=\"justify\">\n        <strong>Forward Looking Statements<\/strong><br \/>\n        <br \/>This press release may contain forward-looking statements and estimates, including statements regarding DBV\u2019s forecast of its cash runway, designs of DBV\u2019s anticipated clinical trials, DBV\u2019s planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, the ability of any of DBV\u2019s product candidates, if approved, to improve the lives of patients with food allergies, and the outcome of any litigation. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV\u2019s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, including the impact of the COVID-19 pandemic, and DBV\u2019s ability to successfully execute on its budget discipline measures. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV\u2019s regulatory filings with the French Autorit\u00e9 des March\u00e9s Financiers (\u201cAMF\u201d), DBV\u2019s filings and reports with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), including in DBV\u2019s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 2, 2023, and future filings and reports made with the AMF and SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact <\/strong><br \/>\n        <br \/>Katie Matthews<br \/>DBV Technologies<br \/>+1 857-529-2563<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UWK0WR1OvqIpnHh0Lw1CyRXMwfVW4FdNqqOHP_vboF_GMZSgCNObHMTwQ_LpGxYNXGhfHuAF5gnOrDJKZ218xt6omEAjng60sd5dWZvKR0NDA0dszoYeqPa58ry81W2mcuFew774Kw2r4EG9M6S2jA==\" rel=\"nofollow noopener\" target=\"_blank\">katie.matthews@dbv-technologies.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Angela Marcucci<br \/>DBV Technologies<br \/>+1\u00a0646-842-2393<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gtPyynpBDByu0oWCpXMWeYNJVNlb6CGhCOJkHn5-TEcUioYffothv4xDHbj6DN78c7aN_19ziyqZXSETe1HEJY9FxOeMm53tksWxwVMvy7wFTe0zRkSKnhfsxoSNaLXa6iiiob_cqzWnFw33jKoATw==\" rel=\"nofollow noopener\" target=\"_blank\">angela.marcucci@dbv-technologies.com<\/a><\/p>\n<p align=\"justify\">Viaskin and EPIT are trademarks of DBV Technologies.<\/p>\n<p \/>\n<p id=\"gnw_attachments_section-header\">\n        <strong>Attachment<\/strong>\n      <\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n          <a target=\"_blank\" href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/f4f830b9-e422-4fe8-961f-cf3d57f22147\" rel=\"noopener\">PDF Version<\/a>\n        <\/li>\n<\/ul>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzMjU0OCM0MDE1ODkxMjYjMTAxMTE1Mg==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/OWJmMzZiYzItMzFmMi00ZmEwLWJjYjgtNzMyMWNjMmU3MGVlLTEwMTExNTI=\/tiny\/DBV-Technologies-S-A-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Montrouge, France, July 31, 2023 DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Stud ies and Reports Second Quarter and Half-Year 2023 Financial Results R eceived feedback from U.S. Food and Drug Administration (FDA) on DBV\u2019s two supplemental safety stud ies in toddlers ( ages 1 \u2013 3 years) and children ( ages 4 \u2013 7 years) . The two Phase 3 pivotal safety studies will be named COMFORT Toddlers (1 \u2013 3 years) and COMFORT Children (4 \u2013 7 years). COMFORT Toddlers will be a 6-month safety study, consistent with agreement previously reached with FDA on the COMFORT Children safety study. The Company expects to seek final alignment with FDA on the COMFORT protocols &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-773939","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Montrouge, France, July 31, 2023 DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Stud ies and Reports Second Quarter and Half-Year 2023 Financial Results R eceived feedback from U.S. Food and Drug Administration (FDA) on DBV\u2019s two supplemental safety stud ies in toddlers ( ages 1 \u2013 3 years) and children ( ages 4 \u2013 7 years) . The two Phase 3 pivotal safety studies will be named COMFORT Toddlers (1 \u2013 3 years) and COMFORT Children (4 \u2013 7 years). COMFORT Toddlers will be a 6-month safety study, consistent with agreement previously reached with FDA on the COMFORT Children safety study. The Company expects to seek final alignment with FDA on the COMFORT protocols &hellip; Continue reading &quot;DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-01T00:27:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzMjU0OCM0MDE1ODkxMjYjMTAxMTE1Mg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results\",\"datePublished\":\"2023-08-01T00:27:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\\\/\"},\"wordCount\":2167,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgzMjU0OCM0MDE1ODkxMjYjMTAxMTE1Mg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\\\/\",\"name\":\"DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgzMjU0OCM0MDE1ODkxMjYjMTAxMTE1Mg==\",\"datePublished\":\"2023-08-01T00:27:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgzMjU0OCM0MDE1ODkxMjYjMTAxMTE1Mg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgzMjU0OCM0MDE1ODkxMjYjMTAxMTE1Mg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results - Market Newsdesk","og_description":"Montrouge, France, July 31, 2023 DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Stud ies and Reports Second Quarter and Half-Year 2023 Financial Results R eceived feedback from U.S. Food and Drug Administration (FDA) on DBV\u2019s two supplemental safety stud ies in toddlers ( ages 1 \u2013 3 years) and children ( ages 4 \u2013 7 years) . The two Phase 3 pivotal safety studies will be named COMFORT Toddlers (1 \u2013 3 years) and COMFORT Children (4 \u2013 7 years). COMFORT Toddlers will be a 6-month safety study, consistent with agreement previously reached with FDA on the COMFORT Children safety study. The Company expects to seek final alignment with FDA on the COMFORT protocols &hellip; Continue reading \"DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\/","og_site_name":"Market Newsdesk","article_published_time":"2023-08-01T00:27:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzMjU0OCM0MDE1ODkxMjYjMTAxMTE1Mg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results","datePublished":"2023-08-01T00:27:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\/"},"wordCount":2167,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzMjU0OCM0MDE1ODkxMjYjMTAxMTE1Mg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\/","name":"DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzMjU0OCM0MDE1ODkxMjYjMTAxMTE1Mg==","datePublished":"2023-08-01T00:27:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzMjU0OCM0MDE1ODkxMjYjMTAxMTE1Mg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzMjU0OCM0MDE1ODkxMjYjMTAxMTE1Mg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-studies-and-reports-second-quarter-and-half-year-2023-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/773939","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=773939"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/773939\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=773939"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=773939"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=773939"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}